NeoStem to launch $16.5m public offering Print E-mail
By Deborah Sterescu -   
Tuesday, 19 July 2011 17:55
Cell therapy company NeoStem (AMEX:NBS) announced Tuesday that it plans to raise $16.5 million through an underwritten public offering of its shares.

The company will issue 13.75 million units at $1.20 per unit. Each unit will consist of one common share and a warrant to purchas three quarters of a share at a per share price of $1.45.

NeoStem expects to receive $16.5 million in gross proceeds, prior to deducting underwriting discounts and commissions, as well as offering expenses.

The new funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units and other general corporate purposes, it said.

Lazard Capital Markets and JMP Securities acted as joint bookrunners for the offering, while Morgan Joseph TriArtisan, Maxim Group and National Securities Corporation acted as co-managers.

The financing is expected to close around July 22, subject to customary closing conditions.

Since starting out as a stem-cell storage company, NeoStem has branched out into cell therapeutics, engaged in the development and manufacturing of cell-based therapies.

Its January 2011 acquisition of Progenitor Cell Therapy and its recent announcement of its plans to acquire Amorcyte position the company for further growth.

Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here 

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus